Human Acute Myeloid Leukemia Bone Marrow CD34+ Cells (Newly Diagnosed/Untreated)

Description

Human Acute Myeloid Leukemia CD34+ cells are positively isolated from bone marrow mononuclear cells of adult acute myeloid leukemia (AML) patients (typically aged 40–75) using direct CD34 MicroBead-based immunomagnetic separation. These primary cells are enriched for malignant hematopoietic stem and progenitor cells, exhibiting blast-like morphology and limited proliferative capacity in vitro. They commonly overexpress myeloid markers such as CD33, CD13, and CD117, and frequently harbor mutations including FLT3-ITD and NPM1, detectable by qPCR or FISH. These cells are ideal for studying leukemogenesis, therapy strategies for AML CD34+ cells, untreated acute myeloid leukemia CD34+, and genetic profiling of CD34+ cells in AML. To ensure the quality of these primary cells, repeated freeze-thaw cycles are not recommended due to the fragile nature of these cells.The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.